Perrigo UK FINCO Limited Partnership

Perrigo UK FINCO Limited Partnership ("Perrigo UK Finco") is a United Kingdom limited partnership registered in England and Wales (Companies House no. LP010976) on 7 December 2005, with its registered office at Wrafton Laboratories, Wrafton, Braunton, Devon. It is a subsidiary of Perrigo Company plc (NYSE: PRGO), the Ireland-domiciled consumer self-care company that appears in Perrigo's SEC subsidiary filings. Perrigo Company plc was incorporated in Ireland in 2013 (successor to Michigan-based Perrigo Company) and is headquartered in Dublin, with major U.S. operations in Michigan. Public sources put the parent at roughly 8,100–8,400 employees and FY2024 net sales of about $4.4 billion.

The entity is an operating pharmaceutical affiliate, not a patent-assertion vehicle. During the period of the tracked litigation it functioned within Perrigo's prescription (Rx) Pharmaceuticals segment, which developed and filed Abbreviated New Drug Applications for generic topical and nasal products for the U.S. market — for example generic naloxone nasal spray, azelaic acid foam, clindamycin phosphate, and ivermectin cream. (Perrigo has since divested its Rx Pharmaceuticals business; the current corporate role of this specific partnership is not clearly documented in public sources.)

Litigation posture: the case data show 0 cases as plaintiff and 1 as defendant — consistent with an operating company defending ANDA/Paragraph IV patent suits brought by brand-drug holders, rather than a two-way litigant.

The tracked case, Adapt Pharma Operations Limited et al. v. Perrigo UK FINCO Limited Partnership (D.N.J. No. 2:18-cv-15287; consolidated with 2:18-cv-16987), was filed in late 2018 by Adapt Pharma and Opiant Pharmaceuticals over Perrigo's ANDA for a generic NARCAN (naloxone hydrochloride) nasal spray. The parties settled, and a consent judgment entered 2 March 2020 enjoined Perrigo from infringing the licensed patents (including U.S. 9,211,253 and 10,085,937) on its ANDA product. Venue was the District of New Jersey, not a plaintiff-friendly Texas district, which is typical for Hatch-Waxman suits tied to the brand holder's home forum.